Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2326 (LINC02326) is a member of the long intergenic non-coding RNA (lincRNA) family, comprising RNA transcripts longer than 200 nucleotides that do not overlap annotated protein-coding genes[1][5]. LINC02326, as with other lincRNAs, is presumed to play a role in transcriptional regulation, chromatin remodeling, RNA stabilization, and possibly enhancer-associated gene control[5]. Its precise biological function, molecular targets, or links to disease remain uncharacterized in current literature. LINC02326 is not considered a classical therapeutic target, such as a receptor, enzyme, or transporter; it is instead a non-coding regulatory RNA without established roles as a drug target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2326 (LINC02326).